By examining differentially expressed genes (DEGs) generated by immune and stromal components in CESC samples, we found that CXCR3 may be a viable biomarker for TME alteration and immunotherapeutic status in CESC. The gene discussed is CXCR3; the disease is cervical squamous cell carcinoma.